Batavia Biosciences has successfully produced vaccine material for a Phase I clinical trial of IAVI’s Lassa fever vaccine candidate, rVSV∆G-LASV-GPC. The vaccine candidate was manufactured using Batavia’s intensified vaccine manufacturing platform (HIP-Vax). This platform uses the novel fixed-bed bioreactor ‘scale-X’, enabling the use of high cell densities during manufacturing.   IAVI’s Lassa fever vaccine candidate, rVSV∆G-LASV-GPC, uses a recombinant vesicular stomatitis virus (rVSV) vector—t...